CD19
41 programs · 41 companies
Programs
41
Companies
41
Active Trials
26
Targeting CD19
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | NBMigraine | |
| NVS-6974 | Novartis | Preclinical | Parkinson'sET | |
| Voxarasimod | Merck & Co | Phase 1/2 | NB | |
| Tirarelsin | TG Therapeutics | NDA/BLA | RSVT2D | |
| VYG-2926 | Voyager | NDA/BLA | MDDPSP | |
| SDG-1247 | Schrodinger | Phase 1 | BCCProstate Ca | |
| Talatuximab | Sobi | Phase 1/2 | PsA | |
| 452-8741 | Ono Pharma | Phase 1 | PBCSMA | |
| CHA-IIT-927 | Charite Berlin | Phase 1/2 | HCC | |
| HOV-IIT-284 | HOVON | Phase 1 | Bladder Ca | |
| Nirasertib | Scorpion | Phase 2/3 | GISTMCC | |
| THI-6273 | Third Rock | Phase 2 | Huntington'sACC | |
| INH-5545 | Inhibrx (Sanofi) | Phase 3 | CMLMelanoma | |
| UNC-3197 | Unicycive Therapeutics | NDA/BLA | RCCPsoriasis | |
| Cevirasimod | Crinetics Pharma | Preclinical | Thymoma | |
| Kemanesiran | Aerpio Pharmaceutics | Phase 3 | EoE | |
| AGO-242 | Agora Inc | Preclinical | HNSCCCTCL | |
| APM-3452 | Aptorum Group | Phase 1/2 | EpilepsyOvarian Ca | |
| Niracilimab | Genprobe (Hologic) | Phase 3 | Endometrial CaLN | |
| CHI-3542 | China Biologic | Phase 2 | HNSCCBreast Ca | |
| ALE-9377 | Alexion (AZN) | Approved | GAHCC | |
| 212-6798 | JW Therapeutics | Phase 1/2 | Breast CaParkinson's | |
| INT-430 | Interline Ther | Phase 2/3 | RACholangiocarcinoma | |
| Elrabrutinib | Nvelop Ther | Phase 3 | Cervical Ca | |
| PBL-1430 | Panbela | Phase 1/2 | Ovarian CaBladder Ca | |
| HAR-9296 | Harmony Bio | Phase 1 | HNSCCCeliac | |
| STA-IIT-233 | Stanford Med | Phase 3 | HS | |
| Mirisertib | Mimetogen | Phase 3 | FabryADPKD | |
| Zorizasiran | Avanir (Otsuka) | Phase 1 | HNSCCLGS | |
| GEN-IIT-955 | Genethon | Phase 2/3 | Cholangiocarcinoma | |
| Datomavacamten | Menarini | Preclinical | MSPSP | |
| Doxacilimab | Polynovo | Preclinical | FTD | |
| Olpazumab | Myovant Sciences | Approved | Ewing Sarcoma | |
| POL-2127 | Polyphor | Approved | RCC | |
| SYN-2281 | Syncona | Phase 1/2 | MCCPNH | |
| STA-4766 | Stallergenes Greer | Phase 1/2 | PSPT2D | |
| BIO-IIT-742 | Bio Farma | Phase 3 | IgAN | |
| SEV-IIT-334 | Severance Hospital | Phase 1 | HNSCC | |
| Tixasotorasib | Square Pharma | NDA/BLA | IgANWilms | |
| Teralucimab | BioLife Solutions | Phase 1 | MelanomaAS | |
| ELA-3520 | Elanco | Phase 2 | SCDALS |